Description

This edition of the Future Tech TOE primarily encompasses comprehensive analyses of key emerging therapies across multiple sclerosis (MS). The service also includes treatment overviews, clinical pipeline analysis, IP and funding analysis, and emerging innovations across MS therapies. Furthermore, the research features the impact of key technology drivers and restraints for the global MS therapeutic industry, while providing an overview of the emerging technological landscape for MS treatments.

The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Multiple sclerosis, stem cell therapy, Ocrevus, Ocrelizumab, neurodegenerative disease, Natalizumab, Alemtuzumab, Fingolimod, Teriflunomide, autologous hematopoietic stem cell transplantation (AHSCT), monoclonal antibody treatment